Boston Scientific Corp (BSX.N)
11.15USD
1 Aug 2013
$0.23 (+2.11%)
$10.92
$10.96
$11.49
$10.92
5,261,517
3,075,148
$11.49
$5.04
About
Overall
| Beta: | 1.23 |
| Market Cap (Mil.): | $14,732.09 |
| Shares Outstanding (Mil.): | 1,349.09 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| BSX.N | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 66.39 | 37.76 |
| EPS (TTM): | -0.60 | -- | -- |
| ROI: | -5.42 | 4.99 | 18.76 |
| ROE: | -11.54 | 9.80 | 19.59 |
UPDATE 3-Boston Scientific signals new growth, shares up 11 pct
* Revenue from stents, implantable defibrillators stabilizes (Adds analyst comments, company comments, financial details, updates stock price)
REFILE-Boston Scientific reports second-quarter profit as revenue dips
July 25 - Boston Scientific Corp on Thursday reported a second-quarter profit, reversing a year-earlier loss, and said sales in its medical surgical device business had risen.
RPT-INSIGHT-Apple controversy lays bare complex Irish tax web
* More than 40 percent of S&P 500 have subsidiaries in Ireland
Fitch Affirms Boston Scientific's IDR at 'BBB-'; Outlook Stable
(The following statement was released by the rating agency) CHICAGO, July 12 (Fitch) Fitch Ratings has affirmed Boston Scientific Corp.'s (NYSE: BSX) Issuer Default Rating (IDR) at 'BBB-'. A full list of BSX's ratings follows at the end of this release. The rating action applies to approximately $4.25 billion of debt. The Rating Outlook is Stable. KEY RATING DRIVERS: --Fitch expects BSX will operate with relatively stable leverage (total debt/EBITDA) of 2.3 times (x) to 2.5x during the next
Boston Sci to buy Bard electrophysiology unit for $275 mln
WASHINGTON, June 28 - Medical device maker Boston Scientific Corp said on Friday it would buy the electrophysiology (EP) business of C.R. Bard Inc for $275 million in cash, expanding its roster of products that help treat patients with an abnormal heartbeat.
Boston Scientific says on path to growth
- Medical device maker Boston Scientific Corp reported better-than-expected first-quarter results on Thursday, which the company said will put it on the path to return to growth.
UPDATE 2-Boston Scientific says on path to growth
April 25 - Medical device maker Boston Scientific Corp reported better-than-expected first-quarter results on Thursday, which the company said will put it on the path to return to growth.
Boston Scientific posts loss on restructuring, lawsuits
- Medical device maker Boston Scientific Corp posted a first-quarter loss on Thursday as it took $578 million in charges for litigation and restructuring, including reducing its workforce.
Boston Scientific posts first-quarter loss
April 25 - Medical device maker Boston Scientific Corp on Thursday posted a first-quarter loss due to $578 million in restructuring, litigation and other charges.
Boston Scientific atrial fibrillation device proves safe -study
SAN FRANCISCO/CHICAGO, March 9 - A tiny upside down umbrella-shaped device implanted on the heart to prevent stroke in patients with a dangerous irregular heart rhythm known as atrial fibrillation appeared to be safe in a highly anticipated clinical trial, providing an alternative to clot-preventing blood thinners.
Competitors
| Price | Change | |
|---|---|---|
| Johnson & Johnson (JNJ.N) | $93.77 | +0.27 |
| Medtronic, Inc. (MDT.N) | $55.49 | +0.25 |
| Abbott Laboratories (ABT.N) | $36.84 | +0.21 |
| St. Jude Medical, Inc. (STJ.N) | $53.00 | +0.61 |
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Trading Report for (BSX). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

